The FDA has approved Striverdi Respimat (olodaterol; Boehringer Ingelheim) 5mcg inhalation spray for the treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema with airflow obstruction.
The safety and efficacy of Striverdi Respimat was studied in a Phase 3 clinical trial program including data from 48-week and 6-week duration trials in over 4,900 patients with COPD. Patients treated with Striverdi Respimat showed improved lung function compared to placebo as measured by forced expiratory volume in one second (FEV1).
Olodaterol is a long-acting beta-adrenergic agonist (LABA) that helps muscles around the airways in the lungs stay relaxed to prevent symptoms. Olodaterol exerts its pharmacological effects by binding and activation of beta2-adrenoceptors after topical administration by inhalation. Activation of these receptors in the airways results in a stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3′, 5′ adenosine monophosphate (cAMP). Elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells.
Striverdi Respimat will be available in a carton containing a single cartridge for use with the Striverdi Respimat Inhaler. Each inhaler contains 60 metered actuations delivering 2.5mcg olodateral HCl per actuation.
For more information call (800) 459-9906 or visit Boehringer-Ingelheim.com.